Published in Cancer Weekly, August 29th, 2000
"For the development of peptide-based immunotherapies, the identification of additional tumor antigens and T-cell epitopes is required," stated Y.S. Sun and colleagues, University Heidelberg, Germany. "Because HLA-A*0201 is the most common allele in Caucasians, who represent the majority of patients with melanomas, six peptides carrying an HLA-A*0201 motif were synthesized from tyrosinase-related protein-2 (TRP2) melanoma antigen and tested for binding affinity to the HLA allele using processing-defective T2...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.